Senior Director of Finance
BrainChild Bio
Senior Director of Finance
BrainChild Bio
CAR T therapies targeting CNS tumors
Salary Range: 205000 to 275000 (Currency: USD) (Pay period: per-year-salary)
About Brainchild Bio
Brainchild Bio is a clinical-stage biotech developing new therapies for children with brain cancer. Backed by a $116M Series A, we are headquartered in Seattle with a growing presence in Texas. We are building the company that will carry our programs through the clinic, and we need operators who can scale with us.
The Role
The Senior Director of Finance owns Brainchild Bio's day-to-day finance engine and serves as the primary finance partner to R&D, product operations, clinical, and business operations leaders. The role reports to the CFO and will interact with the entire executive team.
This is a hands-on leadership role at a company that is still building its financial infrastructure. You will improve and, in some cases, establish processes, systems, and controls that scale from Series A to later-stage financing and, eventually, public-company readiness.
Key Responsibilities
Financial planning and reporting
Business partnering
Accounting operations
Team and systems
Qualifications
Required
Preferred
What Success Looks Like in Year One
Location: Remote, with a preference for candidates based in the Seattle area
CAR T therapies targeting CNS tumors
What BrainChild Bio does: It develops CAR T cell therapies to treat tumors in the central nervous system, focusing on children first and then expanding to adults with glioblastoma. How its product works: The lead therapy, BCB-276, uses a patient’s own T cells engineered to target B7-H3, and is given directly into the cerebrospinal fluid to reach brain and spine tumors. The company is also advancing a triple-targeting candidate, BCB-214, toward initial glioblastoma testing. How it differs from competitors: BrainChild Bio relies on autologous CAR T cells delivered locoregionally into CSF, with technology licensed from Seattle Children’s and strong ties to that institution, aiming at pediatric DIPG and other CNS cancers. What its goal is: To complete the Phase 2 ILLUMINATE trial to support a future regulatory filing for BCB-276 and to broaden its pipeline for CNS tumors, including early work on glioblastoma, supported by a recent $116 million Series A.
Explore more opportunities at BrainChild Bio